Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary fibrosis
Biotech
Analysts unshaken by patient death in BMS lung fibrosis trial
Analysts were quick to dismiss concerns that the liver toxicity seen with BMS' admilparant spell larger trouble for the LPA1 drug class.
Darren Incorvaia
Oct 1, 2026 10:22am
Fierce Pharma
Avalyn adds $100M to advance inhaled versions of IPF pills
Jul 22, 2025 10:44am
GSK and Boston scientists team up to tackle lung diseases
Oct 18, 2024 11:26am
Vicore's IPF drug improves lung function in phase 2 win
May 20, 2024 2:00am
BMS charts 2nd pulmonary fibrosis win with LPA1 antagonist
Sep 11, 2023 10:05am
BMS' pulmonary fibrosis drug reduces lung function decline
May 22, 2023 1:05pm
